Molekulární faktory atherogeneze v chronické renální insuficienci s použitím experimentálního modelu chronické inhibice syntézy oxidu dusnatého a jeho ovlivnění inhibicí HMG-CoA reduktázy
The experimental part of the thesis covered the markers involved in nitric oxide deficiency model in rats. The analogue of arginine N-nitro- L -arginine-methyl ester ( L -NAME) was used. L -NAME administration resulted in sustained elevation of BP, decreased GFR, and in higher albuminuria compared t...
Main Author: | |
---|---|
Other Authors: | |
Format: | Doctoral Thesis |
Language: | Czech |
Published: |
2008
|
Online Access: | http://www.nusl.cz/ntk/nusl-294605 |
id |
ndltd-nusl.cz-oai-invenio.nusl.cz-294605 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-nusl.cz-oai-invenio.nusl.cz-2946052018-10-03T04:29:34Z Molekulární faktory atherogeneze v chronické renální insuficienci s použitím experimentálního modelu chronické inhibice syntézy oxidu dusnatého a jeho ovlivnění inhibicí HMG-CoA reduktázy Molecular factors of artherogenesis in chronic kidney disease with experimental model of chronic inhibition of Nitric Oxide Synthesis and its Effect of HMG-CoA reductase inhibitoin Lecian, Dalibor Matouš, Bohuslav Tesař, Vladimír Zadražil, Josef The experimental part of the thesis covered the markers involved in nitric oxide deficiency model in rats. The analogue of arginine N-nitro- L -arginine-methyl ester ( L -NAME) was used. L -NAME administration resulted in sustained elevation of BP, decreased GFR, and in higher albuminuria compared to control animals. The administration of hypolipidemic drug - atorvastatin to Wistar rats was studied. The statin used caused lower albuminuria and prevented decreases in GFR in L -NAME rats without having an impact on hypertension. CAV1 protein expression was similar in all groups of rats. In contrast, VEGF expression and RhoA activity was increased in L -NAME-treated animals, and normalized with coadministration of atorvastatin. Clinical part of the thesis focused on the analysis of markers of oxidative stress in obese and non-obese patients with CKD and after kidney transplantation. The patients with CKD had elevated serum concentrations of AGEs, sRAGE and ADMA with the maximal concentrations of AGEs in the patients on hemodialysis. The successful kidney transplantation decreases the AGEs, sRAGE and ADMA concentrations but not to normal value according to general population. Patients with obesity exhibited lower concentrations of sRAGE in CKD as a protective factor for cardiovascular disease. Concentrations of... 2008 info:eu-repo/semantics/doctoralThesis http://www.nusl.cz/ntk/nusl-294605 cze info:eu-repo/semantics/restrictedAccess |
collection |
NDLTD |
language |
Czech |
format |
Doctoral Thesis |
sources |
NDLTD |
description |
The experimental part of the thesis covered the markers involved in nitric oxide deficiency model in rats. The analogue of arginine N-nitro- L -arginine-methyl ester ( L -NAME) was used. L -NAME administration resulted in sustained elevation of BP, decreased GFR, and in higher albuminuria compared to control animals. The administration of hypolipidemic drug - atorvastatin to Wistar rats was studied. The statin used caused lower albuminuria and prevented decreases in GFR in L -NAME rats without having an impact on hypertension. CAV1 protein expression was similar in all groups of rats. In contrast, VEGF expression and RhoA activity was increased in L -NAME-treated animals, and normalized with coadministration of atorvastatin. Clinical part of the thesis focused on the analysis of markers of oxidative stress in obese and non-obese patients with CKD and after kidney transplantation. The patients with CKD had elevated serum concentrations of AGEs, sRAGE and ADMA with the maximal concentrations of AGEs in the patients on hemodialysis. The successful kidney transplantation decreases the AGEs, sRAGE and ADMA concentrations but not to normal value according to general population. Patients with obesity exhibited lower concentrations of sRAGE in CKD as a protective factor for cardiovascular disease. Concentrations of... |
author2 |
Matouš, Bohuslav |
author_facet |
Matouš, Bohuslav Lecian, Dalibor |
author |
Lecian, Dalibor |
spellingShingle |
Lecian, Dalibor Molekulární faktory atherogeneze v chronické renální insuficienci s použitím experimentálního modelu chronické inhibice syntézy oxidu dusnatého a jeho ovlivnění inhibicí HMG-CoA reduktázy |
author_sort |
Lecian, Dalibor |
title |
Molekulární faktory atherogeneze v chronické renální insuficienci s použitím experimentálního modelu chronické inhibice syntézy oxidu dusnatého a jeho ovlivnění inhibicí HMG-CoA reduktázy |
title_short |
Molekulární faktory atherogeneze v chronické renální insuficienci s použitím experimentálního modelu chronické inhibice syntézy oxidu dusnatého a jeho ovlivnění inhibicí HMG-CoA reduktázy |
title_full |
Molekulární faktory atherogeneze v chronické renální insuficienci s použitím experimentálního modelu chronické inhibice syntézy oxidu dusnatého a jeho ovlivnění inhibicí HMG-CoA reduktázy |
title_fullStr |
Molekulární faktory atherogeneze v chronické renální insuficienci s použitím experimentálního modelu chronické inhibice syntézy oxidu dusnatého a jeho ovlivnění inhibicí HMG-CoA reduktázy |
title_full_unstemmed |
Molekulární faktory atherogeneze v chronické renální insuficienci s použitím experimentálního modelu chronické inhibice syntézy oxidu dusnatého a jeho ovlivnění inhibicí HMG-CoA reduktázy |
title_sort |
molekulární faktory atherogeneze v chronické renální insuficienci s použitím experimentálního modelu chronické inhibice syntézy oxidu dusnatého a jeho ovlivnění inhibicí hmg-coa reduktázy |
publishDate |
2008 |
url |
http://www.nusl.cz/ntk/nusl-294605 |
work_keys_str_mv |
AT leciandalibor molekularnifaktoryatherogenezevchronickerenalniinsuficiencispouzitimexperimentalnihomodeluchronickeinhibicesyntezyoxidudusnatehoajehoovlivneniinhibicihmgcoareduktazy AT leciandalibor molecularfactorsofartherogenesisinchronickidneydiseasewithexperimentalmodelofchronicinhibitionofnitricoxidesynthesisanditseffectofhmgcoareductaseinhibitoin |
_version_ |
1718759039233425408 |